{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-098668","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.432837+00:00","generated_at":"2026-06-10T23:25:53.773568+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director","bullets":["Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.","Company appointed Dr. Stephen Harrison as Consultant Medical Director; he chairs the Scientific Advisory Board.","Dr. Harrison previously served as Consultant Medical Director from Oct 2019 to Feb 2021; leads Pinnacle Clinical Research."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-098668","json":"https://secwatch.observer/filing/0001104659-23-098668.json","markdown":"https://secwatch.observer/filing/0001104659-23-098668.md","text":"https://secwatch.observer/filing/0001104659-23-098668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/tm2325511d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:25:53.773568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dd8425248","claim":"Stephen Harrison was appointed as Consultant Medical Director at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Consultant Medical Director"}],"fact_type":"executive_change"},{"claim_id":"6cd28005c2","claim":"Todd Hobbs resigned as Chief Medical Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}